Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: The perfect personalized cancer therapy: cancer vaccines against neoantigens

Fig. 2

Personalized NCV in the context of current immunotherapy, the three dimensions are defined by tumor infiltrating lymphocytes (TILs), mutational load (ML) and tumor heterogeneity (TH). Patients in the lower right panel (TIL−ML+TH+) may benefit from Neoantigen cancer vaccine (NCV) approach whereas patients in the upper right panel (TILs+ML+TH−) respond more to immune checkpoint inhibitors (ICI)

Back to article page